The Methodist Hospital Cancer Center
Welcome,         Profile    Billing    Logout  
 13 Trials 
10 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chang, Jenny
STOMP, NCT03004183: SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC

Completed
2
57
US
ADV/HSV-tk, Valacyclovir, valacyclovir hydrochloride, SBRT, Pembrolizumab, Keytruda
The Methodist Hospital Research Institute, Merck Sharp & Dohme LLC
Metastatic Non-small Cell Lung Cancer, Metastatic Triple-negative Breast Cancer
07/22
01/24
NCT05305924: Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

Recruiting
2
28
US
Fulvestrant Run-In, Abemaciclib, Fulvestrant
The Methodist Hospital Research Institute, Eli Lilly and Company
ER-Positive Breast Cancer, HER2-negative Breast Cancer
03/25
12/26
INTEGRAL, NCT04095689: Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer

Suspended
2
30
US
Docetaxel, Taxotere, Pembrolizumab, Keytruda, IL-12 gene therapy
The Methodist Hospital Research Institute, Merck Sharp & Dohme LLC
Triple Negative Breast Cancer, Anthracycline-refractory TNBC
06/24
12/24
DTP Trial, NCT03820141: Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

Recruiting
2
39
US
Durvalumab, IMFINZI, MEDI4736, Trastuzumab, Herceptin, Pertuzumab, Perjeta
The Methodist Hospital Research Institute, AstraZeneca
Breast Cancer
09/24
02/25
NCT03804944: Converting HR+ Breast Cancer Into an Individualized Vaccine

Recruiting
2
100
US
Focal Radiation therapy, Pembrolizumab (200mg IV for 30 minutes, CDX-301
Weill Medical College of Cornell University, United States Department of Defense, Merck Sharp & Dohme LLC, Celldex Therapeutics
Breast Cancer
12/25
12/27
PRESERVE-001, NCT04140526: Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Recruiting
1/2
733
US, RoW
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, Keytruda, MK3475, Docetaxel, Taxotere, Docefrez
OncoC4, Inc., National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
06/26
12/27
NCT03742245: Olaparib in Combination with Vorinostat in Patients with Relapsed/Refractory And/or Metastatic Breast Cancer

Recruiting
1
28
US
Olaparib, AZD2281, KU-0059436, Lynparza, Vorinostat, Suberanilohydroxamic acid, Zolinza
The Methodist Hospital Research Institute, AstraZeneca
Breast Cancer Metastatic, Breast Cancer
09/25
03/26
Singh, Monisha
DDRiver Solid Tumours 301, NCT04170153: Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Active, not recruiting
1
161
Europe, Japan, US, RoW
M1774, Tuvusertib, Niraparib
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Metastatic or Locally Advanced Unresectable Solid Tumors
01/26
01/26
Darcourt, Jorge
DORA, NCT03574571 / 2018-002944-10: A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Recruiting
3
738
Europe, US, RoW
Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223
Memorial Sloan Kettering Cancer Center, Bayer
Prostate Cancer
06/26
06/26
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
Research, Cancer Center
No trials found

Download Options